GlaxoSmithKline NZ Limited Sustainability Profile
GlaxoSmithKline NZ Limited, commonly referred to as GSK, is a prominent player in the pharmaceutical and healthcare industry, headquartered in New Zealand. Established in 2000, GSK has made significant strides in developing innovative medicines, vaccines, and consumer healthcare products, focusing on areas such as respiratory, HIV, and immunology. With a strong operational presence across the Asia-Pacific region, GSK is recognised for its commitment to research and development, leading to groundbreaking therapies that address unmet medical needs. The company’s core offerings, including its renowned vaccines and prescription medications, are distinguished by their efficacy and safety profiles. GSK's dedication to sustainability and public health has solidified its market position, making it a trusted name in healthcare. Notable achievements include advancements in vaccine technology and a robust pipeline of new treatments, underscoring GSK's role as a leader in the global healthcare landscape.
DitchCarbon Score
How does GlaxoSmithKline NZ Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GlaxoSmithKline NZ Limited's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GlaxoSmithKline NZ Limited currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of GSK plc, and any climate commitments or emissions data would be cascaded from its parent organisation. GSK plc has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are relevant to GlaxoSmithKline NZ Limited's climate strategy. However, specific reduction targets or achievements for GlaxoSmithKline NZ Limited are not detailed in the available information. As part of its corporate family, GlaxoSmithKline NZ Limited aligns with GSK plc's broader sustainability goals, which focus on reducing carbon emissions across all scopes. The company is committed to addressing climate change and enhancing sustainability practices, although specific metrics or targets for GlaxoSmithKline NZ Limited are not provided. In summary, while GlaxoSmithKline NZ Limited is part of a larger organisation with established climate commitments, it currently lacks specific emissions data and reduction targets at the subsidiary level.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000,000 |
| Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000,000 |
| Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - | 0,000,000,000,000 |
How Carbon Intensive is GlaxoSmithKline NZ Limited's Industry?
How Carbon Intensive is GlaxoSmithKline NZ Limited's Location?
GlaxoSmithKline NZ Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
GlaxoSmithKline NZ Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
